New drugs known as PARP inhibitors are showing promise as treatments for some of the most aggressive types of breast cancer, according to results from early studies. Eric Winer, M.D., our Chief Scientific Advisor, says he’s “extraordinarily encouraged” and new clinical trials may start this summer.